Keytruda(Merck's pembrolizumab)+Pelareorep=1PR and 4SD Merck is making 21 billions selling Keytruda. Combining it with ONCY's Pelareorep would extend the their patent further away beyond 2030...
This is the only time recorded that Keytruda would work with something.
https://ca.finance.yahoo.com/news/merck-earnings-better-expected-keytruda-103855398.html:
Merck has been looking for deals to protect itself from eventual revenue loss as patents on Keytruda begin to expire toward the end of the decade. The company reported nearly $21 billion in Keytruda sales last year. https://www.oncolyticsbiotech.com/press-releases/detail/541/oncolytics-biotech-announces-clinical-and-biomarker-data
- Disease control was achieved in 42% (5/12) of patients, with one patient achieving a partial response and four patients achieving stable disease